SimonMed and Matricis.ai advance women’s health with AI-driven MRI study for earlier endometriosis detection
SCOTTSDALE, Ariz., April 15, 2026 – SimonMed, a leading innovator in advanced imaging and longevity-focused technology, today announced its collaborative study with Matricis.ai, a healthcare technology company developing AI for gynecological applications, to pilot an innovative MRI-based solution designed to improve the detection and evaluation of endometriosis, one of the most prominently underdiagnosed conditions globally impacting women’s health.
The study is timed alongside growing national attention on women’s health. At the center of the collaboration is EndomAI, a workflow-integrated AI detection tool designed for mapping and characterizing endometriosis using MRI. By providing a more standardized diagnostic framework for radiologists and decision support for follow-up care, EndomAI aims to improve clarity and consistency for referring OB/GYN physicians.
Endometriosis is a condition that affects 1 in 10 women of reproductive age worldwide, yet patients wait on average 7-10 years to receive a diagnosis, with nearly 42% of women reporting their pain initially being dismissed as “normal” by physicians. These detrimental delays can have consequences, considering 30-50% of women with endometriosis experience fertility challenges, highlighting the urgent need for earlier, discernible detection.
EndomAI intends to address these diagnostic challenges by:
- Generating standardized reporting templates and structured outputs
- Mapping the distribution and extent of lesions, aiding in surgery planning
- Providing decision support for follow-up care and specialist referrals
“For decades, women experiencing endometriosis symptoms have been told their pain is ‘normal,’ often waiting years for answers. That reality needs to change. At SimonMed, we are focused on using advanced imaging and AI to bring objectivity, clarity, and speed to diagnosis—so patients are not only diagnosed earlier, but truly heard and validated in their care journey,” said Dr. Sean Raj, Chief Innovation and Medical Officer at SimonMed.
The initial pilot phase will include approximately 200 patients with suspected or diagnosed endometriosis undergoing MRI scans at select SimonMed centers. The study will evaluate how AI-assisted reporting affects consistency of diagnoses, lesion detection, and radiologist confidence when communicating findings to referring OB/GYN physicians. All imaging interpretations will remain under the supervision of SimonMed’s board-certified radiologists.
“Gynecological imaging has remained one of the most underexplored frontiers in medical AI, despite the enormous clinical burden associated with conditions such as endometriosis. At Matricis.ai, our mission is to bring advanced AI capabilities to this neglected area of medicine,” said Raphaelle Taub, CEO and co-founder of Matricis.ai. “Through this collaboration with SimonMed, we are launching the first clinical pilot of an AI-assisted MRI workflow specifically designed for endometriosis. Our goal is to demonstrate how our AI can shorten the long diagnostic journey that millions of patients face.”
As one of the largest imaging networks in the country, SimonMed provides a unique platform to evaluate how AI technologies can be integrated into real-world clinical workflows at scale. The collaboration reflects a shared commitment to advancing women’s health through responsible AI adoption, including radiologist training, operational scalability, and long-term clinical impact. To learn more about SimonMed, visit simonmed.com.
To learn more about Matricis.ai, visit matricis.ai.
About SimonMed
Headquartered in Scottsdale, Arizona, SimonMed is one of the largest outpatient diagnostic imaging and health technology providers in the United States. SimonMed operates more than 170 centers across 10 states and is supported by a nationwide team of more than 300 subspecialty-trained, board-certified radiologists. SimonMed provides the full spectrum of diagnostic imaging services from X-ray to complex Cardiac MRI and is a recognized leader in the clinical use of artificial intelligence.
SimonMed Longevity is a division focused on proactive health. It offers whole-body MRI and preventive, multi-modality screening designed to help patients establish a baseline of their health, track changes over time, and identify potential risk earlier—when informed action may help prevent or delay disease.
About Matricis.ai
Matricis.ai is a French healthcare technology company developing an AI platform focused on complex gynecological diseases affecting women’s health and fertility, including endometriosis, adenomyosis, and fibroids. The company’s flagship product, EndomAI, uses deep learning to assist radiologists in detecting, mapping, and characterizing endometriosis from MRI scans. By embedding AI directly into clinical radiology workflows, Matricis.ai aims to improve diagnostic consistency, support surgical planning, and accelerate patient access to specialized care. The company is building a broader AI platform dedicated to gynecological diseases, leveraging the world’s largest curated datasets of annotated gynecological imaging to enable earlier detection and more personalized treatment pathways.
